Freed vs Danaher Corporation

Side-by-side comparison of AI visibility scores, market position, and capabilities

Danaher Corporation leads in AI visibility (92 vs 65)
Freed logo

Freed

ChallengerHealthcare Tech

AI Medical Documentation

AI medical scribe used by 20,000+ clinicians at $99/mo. $20M+ ARR. 32M+ patient visits transcribed. $30M Series A led by Sequoia Capital. Founded 2022, SF. Private.

AI VisibilityBeta
Overall Score
B65
Category Rank
#1 of 1
AI Consensus
61%
Trend
up
Per Platform
ChatGPT
69
Perplexity
60
Gemini
71

About

Freed is an AI medical scribe founded in 2022 by CEO Erez Druk, headquartered in San Francisco. The platform listens to patient-clinician encounters and automatically generates structured clinical notes including SOAP notes, referral letters, patient instructions, and ICD-10/CPT billing codes. Priced at $99/month per clinician vs $25-50/hour for human scribes.

Full profile
Danaher Corporation logo

Danaher Corporation

LeaderHealthcare Tech

Enterprise

Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.

AI VisibilityBeta
Overall Score
A92
Category Rank
#17 of 290
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
96
Perplexity
91
Gemini
85

About

Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).

Full profile

AI Visibility Head-to-Head

65
Overall Score
92
#1
Category Rank
#17
61
AI Consensus
60
up
Trend
stable
69
ChatGPT
96
60
Perplexity
91
71
Gemini
85
56
Claude
98
68
Grok
83

Key Details

Category
AI Medical Documentation
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Freed
AI Medical Documentation

Integrations

Only Freed
Danaher Corporation is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.